Vitamin D supplementation helps reduce atopic dermatitis severity
Increasing serum 25-hydroxyvitamin D (25(OH)D) levels to >20 ng/ml on top of standard therapy may yield reductions in severity of atopic dermatitis, a study has found.
A total of 65 atopic dermatitis patients were randomized to receive either vitamin D3 at 5,000 IU/day (n=33) or placebo (n=32) plus baseline therapy (topical steroid, soap substitute and emollient) for 3 months. Disease severity was assessed according to Hanifin-Rajka criteria and the severity scale (SCORAD).
Analysis included 58 patients. Serum 25(OH)D levels at the end of the intervention were significantly higher in the treated vs placebo group (p<0.001).
At week 12, patients with higher serum levels of 25(OH)D (≥20 ng/ml), regardless of whether they received supplementation, had a lower SCORAD relative to those with lower levels (<20 ng/ml; p<0.001). Furthermore, the majority (n=9; 80 percent) of patients with lower vitamin D levels had moderate–severe atopic dermatitis despite standard treatment.
Increased vitamin D levels (≥20 ng/ml) resulting from supplementation was strongly associated with remission of atopic dermatitis (p=0.03). This association persisted in patients with serum levels of ≥20 and ≥30 ng/ml.
The present data suggest that vitamin D3 be considered as a relevant adjuvant in the treatment of atopic dermatitis, researchers said. The dose administered in the cohort proved to be safe and effective for increasing 25(OH)D to levels of sufficiency in 3 months.
Additional investigation is needed to establish the cost-benefit ratio of measuring serum 25(OH)D in patients with AD, particularly those with poor response to standard treatment or with relapses, researchers added.